SHE: 300404

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CompanyDeals

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

OrbusNeich Medical Group Holdings Limited (HKG: 6929), the medical device company, announced the completion of its acquisition of a 100% equity interest in MC Health S.r.l., an Italian distributor —…

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products
CompanyDeals

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

CompanyDeals

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

CompanyDeals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
CompanyDrug

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China

Boji Medicine's Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
CompanyDeals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
CompanyDrug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

CompanyDeals

Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine